Near-Infrared Assay and Content Uniformity of Tablets - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Near-Infrared Assay and Content Uniformity of Tablets
Near-infrared (NIR) assay and content uniformity of tablets provide fast, accurate means of monitoring tablet production that are in step with FDA's process analytical technology initiative.The authors discuss the process for testing a newly released NIR tablet analyzer to determine instrument precision and accuracy using chlorpheniramine maleate tablets.The data show promising results that could relieve laboratory workload of high-performance liquid chromatography analysis and bring analysis closer to..

Pharmaceutical Technology

Figure 1
Near-infrared spectroscopy (NIRS) is an analytical technique based on absorption measured in the near-infrared region of the electromagnetic spectrum that is between the visible and the mid-infrared (IR). The fundamental absorption bands of functional groups occur in the mid-IR and are very strong. Usually, potassium bromide pellets, mulls, or dilutions are required to bring the absorbances within the linear range of the mid-IR detector. The overtone absorptions of these fundamental bands occur in the NIR spectral region and allow direct measurement without sample preparation because of the relative weakness of absorption. The OH, CH, NH, and SH bonds have the strongest overtone absorbances in the NIR region (1).

Figure 2
There is considerable interest in the ability to test solid-dosage form samples more frequently than the 10 per batch specified by the US Pharmacopeia monograph on content uniformity. Interest has increased in using NIR for tablet assay and content-uniformity testing because of concerns of the European Union for better statistically based sampling and the US Food and Drug Administration's initiative on process analytical technology (PAT) for better understanding and monitoring of production (2). NIR can be used as a rapid at-line analysis method to obtain processing feedback in near real time during a tableting campaign. Transmission NIRS through the tablet has been preferred to reflectance NIRS because of heterogeneity within tablets (3, 4). The reflection NIRS technique may be used for coating analysis, but for bulk tablet analysis, the transmission NIRS technique may yield more consistent results.

Figure 3
Laboratory methods for tablet assay and content uniformity are usually time-consuming because they routinely are done by high-performance liquid chromatography (HPLC), which requires lengthy calibration runs, the mixing of buffers, and the procurement and disposal of volatile solvents. Analyzing 10 tablets for content uniformity may take hours, and the results may not be available to tablet-press operators or for batch release for many days or even weeks after the tablets are compressed. Statistical process control (SPC) techniques can be applied while measuring the tablets with NIR in real time during tableting so that assay and content-uniformity problems can be detected before they go beyond acceptable limits.


Figure 4
Five batches of tablets (0.25-in. diameter and 100-mg weight) with 0 mg (placebo tablets), 0.1 mg, 0.5 mg, 1.0 mg, and 2.0 mg of chlorpheniramine maleate (CPM) per tablet were formulated and compressed on a tablet press (HT-AP 18 SS-U/I rotary tablet press, Elizabeth Hata International, Inc., North Huntingdon, PA).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here